I wouldn't even speculate at this time. That being stated, as shareholders we can see trends developing via the financial statements.
The last 3 quarters have seen total revenues exceed cost of revenues, as well, we saw a double in account receivables from the prior quarter. The pop in receivables is something of interest. Is Pfizer/Zoetis finally kicking in, or is there something we don't know.
If and when CYRX receives additional capital, how will it be allocated. It would be nice to see a reduction in current liabilities. If the liquidity ratio could be in the area of 1 or above, that would be extremely bullish.
In order to really get a feel for analyzing cash flow, we need to see a reduction in operating income or loss, and we haven't as of yet. That number continues to stay stagnant.
News 
Market Data 
Discover 
